FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a
phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and
associated with improved activity in KRAS codon 12-13 wild-type patients. BRAF and other RAS
rare mutations have been suggested as additional potential biomarkers for anti-EGFR agents in
metastatic colo-rectal cancer. The present study aims to demonstrate the feasibility and the
activity of the first-line combination of the GONO-FOLFOXIRI regimen and Panitumumab in
molecularly selected metastatic colo-rectal cancer patients.